Geron Corporation (GERN) Stock Analysis

Q: What is the GERN stock price target?

Take-profit $2.96 (+92.8% upside). Target $2.96 (+93.5%), stop $1.43 (−7.0%), A.R:R 9.4:1.

Q: What are the risks of investing in GERN?

Market cap $0.97B below $1B minimum; Market cap $0.97B below $1B minimum; EARNINGS_PROXIMITY:6d<=7d.

Q: Is GERN overvalued or undervalued?

Geron Corporation trades at a P/E of N/A (forward 25.2). TrendMatrix value score: 7.5/10. Overall verdict: Hold.

Q: What do analysts say about GERN?

13 analysts cover GERN with a consensus score of 3.9/5. Average price target: $3.

HoldModerate ConfidenceUpdated 2026-04-30

Healthcare · Biotechnology

Earnings in 6 days (2026-05-06). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Hold if already holding. Not a fresh buy at $1.53, but acceptable to hold if already in. Reason: Market cap $0.97B below $1B minimum.

$1.53+92.8% A.UpsideScore 5.6/10#36 of 158 Biotechnology

Stop $1.43Target $2.96(analyst − 13%)A.R:R 9.4:1

Analyst target$3.40+122.2%5 analysts

$2.96our TP

$1.53price

$3.40mean

Hold if already holding. Not a fresh buy at $1.53, but acceptable to hold if already in. Reason: Market cap $0.97B below $1B minimum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Market cap $0.97B below $1B minimum. Not in investable universe. Score 5.6/10, moderate confidence.

Passes 6/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on earnings proximity 6d<=7d. Suitability: aggressive.

Thesis

Rewards

No bull case signals

Risks

Market cap $0.97B below $1B minimum

Key Metrics

P/E (TTM)—

P/E (Fwd)25.2

Mkt Cap$968M

EV/EBITDA-14.3

Profit Mgn-45.4%

ROE-33.0%

Rev Growth1.0%

Beta0.67

DividendNone

Rating analysts13

Quality Signals

Piotroski F6/9

Options Flow

P/C0.06bullish

IV112%elevated

Max Pain$1-67.3% vs spot

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

2 floor-breakers

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value7.515%1.13

Quality3.315%0.49

Growth6.315%0.94

Momentum5.110%0.51

Sentiment7.210%0.72

Insider Activity5.010%0.50

Peer Rank3.210%0.32

Technical Setup6.95%0.35

Risk Profile5.05%0.25

Catalyst7.55%0.38

Overall (Σ contributions)5.58

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Growth Rank

2.8

Quality Rank

2.8

Value Rank

7.3

Unprofitable operations — net margin -45.4%. Quality floor flags this regardless of sector context.static

Roe

0.0

Roa

0.0

Operating Margin

0.0

Net Margin

0.0

Fcf Quality

0.0

Rule Of 40

3.0

Moat

5.0

Piotroski F

6.7

Current Ratio

8.3

Gross Margin

10.0

Cash-burning: FCF -43% of revenueNo competitive moatRule of 40: -42 (fail)

GatesEARNINGS PROXIMITY 6d<=7dMomentum 5.1<5.5 (soft — BUY_NOW allowed but watch)Momentum 5.1>=4.5A.R:R 9.4 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARSuitability: Aggressive

RSI

38 · Neutral

↓ 20D MA↓ 50D MA↑ 200D MAGOLDEN CROSSSupport $1.47Resistance $1.84

Price Targets

A.Upside+93.5%

A.R:R9.4:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Market cap $0.97B below $1B minimum

! EARNINGS_PROXIMITY:6d<=7d

Earnings

2/4 beats

Next Earnings2026-05-06 (6d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is GERN stock a buy right now?

Hold if already holding. Not a fresh buy at $1.53, but acceptable to hold if already in. Reason: Market cap $0.97B below $1B minimum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Market cap $0.97B below $1B minimum. Not in investable universe. Target $2.96 (+93.5%), stop $1.43 (−7.0%), A.R:R 9.4:1. Score 5.6/10, moderate confidence.

What is the GERN stock price target?

Take-profit target: $2.96 (+92.8% upside). Target $2.96 (+93.5%), stop $1.43 (−7.0%), A.R:R 9.4:1. Stop-loss: $1.43.

What are the risks of investing in GERN?

Market cap $0.97B below $1B minimum.

Is GERN overvalued or undervalued?

Geron Corporation trades at a P/E of N/A (forward 25.2). TrendMatrix value score: 7.5/10. Verdict: Hold.

What do analysts say about GERN?

13 analysts cover GERN with a consensus score of 3.9/5. Average price target: $3.

What does Geron Corporation do?Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products...

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.